Clidinium bromide, as the fixed-combination with chlordiazepoxide hydrochloride, has been used as an adjunct in the treatment of peptic ulcer disease. However, current epidemiologic and clinical evidence supports a strong association between gastric infection with Helicobacter pylori and the pathogenesis of duodenal and gastric ulcers, and the American College of Gastroenterology (ACG), the National Institutes of Health (NIH), and most clinicians currently recommend that all patients with initial or recurrent duodenal or gastric ulcer and documented H. pylori infection receive anti-infective therapy for treatment of the infection. For a more complete discussion of H. pylori infection, including details about the efficacy of various regimens and rationale for drug selection,
Clidinium bromide is used in combination with chlordiazepoxide hydrochloride in the treatment of functional disturbances of GI motility such as irritable bowel syndrome. Therapeutic benefits achieved with the combination preparation may be attributed to the anxiolytic and/or sedative properties of chlordiazepoxide. As with other antimuscarinics, clidinium has limited efficacy in the treatment of these disorders and should be used only if other measures (e.g., diet, sedation, counseling, amelioration of environmental factors) have been of little or no benefit.